SiliconBeat

Astellas Pharma is appealing directly to the stockholder of CV Therapeutics, offering to give them $16 a share, an offer it has unsuccessfully made twice before to CV’s board, most recently a week ago.

“While we continue to prefer to reach a negotiated agreement Read the rest of this entry »

The board of directors at CV Therapeutics decided to extend by a year the shareholders rights plan they have in place to fend off hostile takeovers. The plan, otherwise known as a poison pill, was set to expire Read the rest of this entry »